KALA
KALA BIO, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.17
−5.48%Sep 29, 2026, 11:30 UTC
KALA Bio signed a non-binding letter of intent to acquire 100% of a privately held U.S.-based management services organization supporting a 50-state telehealth platform for approximately $15 million in cash and KALA stock.
Source:Sep 24, 2026, 11:30 UTC
Kala Bio and Virotek signed a letter of intent with a U.S. DNA testing platform to resell Virotek's suite of genetic testing products, expanding their genetic testing collaboration beyond ophthalmology.
Source:Sep 17, 2026, 11:30 UTC
KALA BIO added Yenvy Truong, founder of The LSM Group, to its advisory team.
Source:Sep 10, 2026, 21:26 UTC
KALA BIO, Inc. signed an exclusive distribution and reseller agreement with Virotek Inc. to distribute Virotek's ophthalmology genetic testing program in the United States for an initial five-year term.
Aug 28, 2026, 00:00 UTC
KALA BIO, Inc. received a notice from NASDAQ on August 27, 2026, stating that it is not in compliance with Listing Rule 5550(a)(2) regarding the minimum bid price requirement, and the company has requested a hearing before a NASDAQ panel.